From the Boston Globe:
Novartis CEO: Easing rules on drug imports may loom
Novartis AG chief executive Daniel Vasella yesterday said that he ''wouldn't be surprised" if US regulators ease rules limiting the importation of cheaper drugs from Canada, but cautioned that would damage the industry's financial footing and wouldn't help patients much.

Speaking to a luncheon sponsored by the Boston College Chief Executives' Club at the Boston Harbor Hotel, Vasella, head of the Swiss pharmaceutical giant, echoed the concerns of other drug executives who worry that proposals in Washington might scare away investors.